Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...

UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study ...

Monument Therapeutics, a stratified medicine company, today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in ...

Monument Therapeutics announced its partnership with the Foundation for the National Institutes of Health (FNIH) to continue testing and advancing MT1988, a treatment option being developed for ...

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to address the cognitive symptoms that have long remained untreated.

MT1988 is designed to be used alongside existing anti-psychotic medications for schizophrenia, to finally address the cognitive symptoms that have long remained untreated.

MANCHESTER, England, Nov. 26, 2024 /PRNewswire/ -- Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical ...

The clinical trial with MT1988 will be co-led by Dr. Scott Woods and Dr. Youngsun Cho from Yale School of Medicine, Dr. Carrie Bearden from University of California, Los Angeles (UCLA), Dr. John ...

Cambridge Cognition’s spin-out company, Monument Therapeutics, has secured a £1.0 million investment to advance its novel schizophrenia treatment, MT1988. This funding is expected to enhance ...